Latest News and Press Releases

SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global acute ischemic stroke (AIS) market is estimated to be valued at US$ 8,517.0 Million in 2021 and is...

MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth...

MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor...

Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II...

MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference,...

MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on...

Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney...

MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor...

Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019 at 7am CT MINNEAPOLIS,...

MINNEAPOLIS, May 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on Monday,...